SOMETHING TO THINK ABOUT

Our Point of View

image
OCTOBER 2018

UnitedHealthcare to Apply Step Therapy to Select Medicare Part B Drugs

Utilizing a CMS 2018 policy update, UnitedHealthcare (UHC) is applying step therapy to select Medicare Part B drug classes beginning in 2019. Because UHC plans represent a quarter of the entire Medicare Advantage market, other plan sponsors may follow suit.

Learn More
image
OCTOBER 2018

Trump’s International Pricing Index Payment (IPI) Model and Pharma

The Trump Administration's proposed international pricing index payment model for Medicare Part B drugs is part of several recent and forthcoming programs designed to follow through on Trump's promise to lower prescription drug prices.

Learn More
image
OCTOBER 2018

Gilead Creates Authorized Generics for Hepatitis C Virus Products Harvoni and Epclusa

Gilead is pursing authorized generics for its hepatitis C virus (HCV) drugs, Harvoni® (ledipasvir/sofosbuvir) and Epclusa® (sofosbuvir/velpatasvir). The creation of authorized generics may become more common if anti-kickback legislation regarding rebates comes to pass.

Learn More
image
OCTOBER 2018

The Trump Administration’s Blueprint to Lower Consumer Drug Prices

The Trump Administration’s plan for the United States Department of Health and Human Services may authorize the creation of demonstration projects, waivers, and experiments that may potentially lower drug prices for Medicare beneficiaries.

Learn More
image
OCTOBER 2018

Improving Diversity and Inclusion in Pharma

Diversity and inclusion have the potential to help the pharmaceutical industry reach larger, more diverse patient populations. Empowering undeserved individuals to take an active role in their health may systematically help to improve population health overall.

Learn More
image
OCTOBER 2018

Defining Value in a Multistakeholder Environment

The market access value proposition for pharmaceutical/biotech products and medical devices requires an approach that is both wide (across organization types) and deep (addressing the needs of multiple stakeholders). These factors drive the need for a multistakeholder value proposition.

Learn More